The New Energy Crisis No One Saw Coming
Free investor report reveals how the electric car initiative is putting the U.S. in peril...and shows how to potentially capitalize on this crisis with a junior mining company.
See how this new energy crisis could create a boom
Michelle L. Basil net worth and biography

Michelle Basil Biography and Net Worth

EVP of Haemonetics
Michelle Basil joined Haemonetics in March 2017 as Executive Vice President, General Counsel. She is responsible for Haemonetics' Legal, Compliance, Corporate Development and Corporate Audits and Controls groups. Prior to joining Haemonetics, Ms. Basil was a Partner and Chair of the Life Sciences Practice Group at the Boston-based law firm Nutter, McClennen & Fish where she was legal counsel to public and private companies and their investors, principally in the life sciences and medical technology industries. At Nutter, Ms. Basil’s practice focused on corporate and securities law, including mergers and acquisitions, strategic collaborations, capital markets transactions, corporate governance and other matters affecting publicly traded companies and their officers and directors. Ms. Basil is admitted to the bar in Massachusetts and holds both a Bachelor of Arts and a Juris Doctor from the University of California at Berkeley.

What is Michelle L. Basil's net worth?

The estimated net worth of Michelle L. Basil is at least $2.75 million as of October 24th, 2022. Ms. Basil owns 32,455 shares of Haemonetics stock worth more than $2,749,263 as of December 6th. This net worth estimate does not reflect any other investments that Ms. Basil may own. Learn More about Michelle L. Basil's net worth.

What is Michelle L. Basil's salary?

As the EVP of Haemonetics Co., Ms. Basil earned a total compensation package of $3,379,734.00 in 2022. Ms. Basil earned a salary of $477,619.00, stock awards of $2,241,162.00, options awards of $349,982.00, non-equity compensation of $293,193.00, and other compensation of $17,778.00. Learn More on Michelle L. Basil's salary.

How do I contact Michelle L. Basil?

The corporate mailing address for Ms. Basil and other Haemonetics executives is 125 Summer Street, Boston MA, 02110. Haemonetics can also be reached via phone at (781) 848-7100 and via email at [email protected] Learn More on Michelle L. Basil's contact information.

Has Michelle L. Basil been buying or selling shares of Haemonetics?

During the last ninety days, Michelle L. Basil has sold $14,470.20 in Haemonetics stock. Most recently, Michelle L. Basil sold 180 shares of the business's stock in a transaction on Monday, October 24th. The shares were sold at an average price of $80.39, for a transaction totalling $14,470.20. Following the completion of the sale, the executive vice president now directly owns 32,455 shares of the company's stock, valued at $2,609,057.45. Learn More on Michelle L. Basil's trading history.

Who are Haemonetics' active insiders?

Haemonetics' insider roster includes Michelle Basil (EVP), William Burke (CFO), Dan Goldstein (VP), Mark Kroll (Director), Anila Lingamneni (EVP), Josep Llorens (EVP), Richard Meelia (Director), Laurie Miller (SVP), Jacqueline Scanlan (SVP), Christopher Simon (CEO), and Stewart Strong (Insider). Learn More on Haemonetics' active insiders.

Are insiders buying or selling shares of Haemonetics?

During the last twelve months, insiders at the medical instruments supplier sold shares 22 times. They sold a total of 62,013 shares worth more than $4,650,299.35. The most recent insider tranaction occured on October, 24th when insider Stewart W Strong sold 75 shares worth more than $6,029.25. Insiders at Haemonetics own 1.7 % of the company. Learn More about insider trades at Haemonetics.

Information on this page was last updated on 10/24/2022.

Michelle L. Basil Insider Trading History at Haemonetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/24/2022Sell180$80.39$14,470.2032,455View SEC Filing Icon  
9/19/2022Sell11,448$78.36$897,065.2832,635View SEC Filing Icon  
9/15/2022Sell33,798$77.89$2,632,526.2235,395View SEC Filing Icon  
6/13/2022Sell277$62.60$17,340.2040,635View SEC Filing Icon  
10/25/2021Sell120$71.93$8,631.60View SEC Filing Icon  
6/14/2021Sell195$59.87$11,674.65View SEC Filing Icon  
6/7/2021Sell442$55.09$24,349.78View SEC Filing Icon  
5/17/2021Sell204$55.97$11,417.88View SEC Filing Icon  
10/23/2020Sell181$106.58$19,290.98View SEC Filing Icon  
6/16/2020Sell24,217$89.56$2,168,874.52View SEC Filing Icon  
6/12/2020Sell203$89.29$18,125.87View SEC Filing Icon  
6/8/2020Sell687$97.03$66,659.61View SEC Filing Icon  
3/9/2020Sell395$98.00$38,710.00View SEC Filing Icon  
10/8/2019Sell8,883$122.34$1,086,746.22View SEC Filing Icon  
6/7/2019Sell7,187$103.49$743,782.63View SEC Filing Icon  
3/7/2019Sell391$83.57$32,675.87View SEC Filing Icon  
6/7/2018Sell457$92.73$42,377.61View SEC Filing Icon  
3/6/2018Sell389$72.23$28,097.47View SEC Filing Icon  
See Full Table

Michelle L. Basil Buying and Selling Activity at Haemonetics

This chart shows Michelle L Basil's buying and selling at Haemonetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Haemonetics Company Overview

Haemonetics logo
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $83.84
Low: $82.97
High: $84.70

50 Day Range

MA: $80.01
Low: $72.05
High: $86.14

2 Week Range

Now: $83.84
Low: $43.50
High: $86.58

Volume

7,445 shs

Average Volume

434,938 shs

Market Capitalization

$4.24 billion

P/E Ratio

50.51

Dividend Yield

N/A

Beta

0.37
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War
Right now, China has the US Military in a stranglehold. They hold a monopoly on one of our most CRITICAL defense elements. But thanks to executive orders from both Biden and Trump...
China's Monopoly Is About To Crumble...